# Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.

Study · id `cardio:ct-nct01649466` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01649466](<https://clinicaltrials.gov/study/NCT01649466>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01649466

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.

## Technical summary

Registry record NCT01649466. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 162 participants (enrolled count; ClinicalTrials.gov record NCT01649466, source copy `cardio:ctgov-nct01649466-2016-11-17`, retrieved 2026-10-26)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01649466, source copy `cardio:ctgov-nct01649466-2016-11-17`, retrieved 2026-10-26)
- Primary completion: 2013-10 (actual) (ClinicalTrials.gov record NCT01649466, source copy `cardio:ctgov-nct01649466-2016-11-17`, retrieved 2026-10-26)
- Completion: 2013-10 (actual) (ClinicalTrials.gov record NCT01649466, source copy `cardio:ctgov-nct01649466-2016-11-17`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT01649466, source copy `cardio:ctgov-nct01649466-2016-11-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01649466-2016-11-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.
- Acronym: BENEFIT
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): LAF237
- Intervention (Drug): Protaphane
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study (`cardio:pubmed-25867771`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f8fa0933af1043242dbad871586fcfb8da328c8c8ae8e849d724ecc8ef9753eb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
